# Sandro Ardizzone

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sandro-ardizzone/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,198 |
| Field | Inflammatory Bowel Disease |
| h-index | 67 |
| i10-index | 199 |
| OpenAlex ID | https://openalex.org/A5071325068 |
| ORCID iD | https://orcid.org/0000-0001-9915-2992 |
| Works | 464 |

## Researcher papers

- [Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders](https://scholariq.org/papers/third-european-evidence-based-consensus-on-diagnosis-and-management-of/)
- [Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines](https://scholariq.org/papers/imaging-techniques-for-assessment-of-inflammatory-bowel-disease-joint-ecco-and/)
- [Mongersen, an Oral <i>SMAD7</i> Antisense Oligonucleotide, and Crohn’s Disease](https://scholariq.org/papers/mongersen-an-oral-i-smad7-i-antisense-oligonucleotide-and-crohn-s-disease/)
- [Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease](https://scholariq.org/papers/advanced-age-is-an-independent-risk-factor-for-severe-infections-and-mortality/)
- [Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection](https://scholariq.org/papers/infliximab-reduces-endoscopic-but-not-clinical-recurrence-of-crohn-s-disease/)
- [Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED–ECCO consensus](https://scholariq.org/papers/role-of-small-bowel-endoscopy-in-the-management-of-patients-with-inflammatory/)
- [The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease☆](https://scholariq.org/papers/the-italian-society-of-gastroenterology-sige-and-the-italian-group-for-the-study/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Autoimmune and Inflammatory Disorders](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders/)
- [Diverticular Disease and Complications](https://scholariq.org/topics/diverticular-disease-and-complications/)
- [Eosinophilic Esophagitis](https://scholariq.org/topics/eosinophilic-esophagitis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.